Mainz Biomed to Attend 2025 Maxim Growth Summit
Mainz Biomed (NASDAQ:MYNZ) will attend the 2025 Maxim Growth Summit in New York City on October 22-23, 2025 at The Hard Rock Hotel NYC. The company, which focuses on molecular genetics diagnostics for early cancer detection, said it will meet one-on-one with institutional investors and senior Maxim analysts during the event.
The summit features keynote speakers and roundtable sessions across sectors including biotechnology, AI, stem cell therapy and more. For the summit agenda visit www.maximgrp.com/2025-growth-summit and for investor information visit mainzbiomed.com/investors/.
Mainz Biomed (NASDAQ:MYNZ) parteciperà al 2025 Maxim Growth Summit a New York City il 22-23 ottobre 2025 al The Hard Rock Hotel NYC. L'azienda, che si concentra sulla diagnostica molecolare genetica per il rilevamento precoce del cancro, ha dichiarato che incontrerà investitori istituzionali e analisti senior di Maxim durante l'evento.
Il summit prevede relatori principali e sessioni di tavola rotonda in settori tra cui biotecnologie, IA, terapie con cellule staminali e altro ancora. Per l'agenda del summit visitare www.maximgrp.com/2025-growth-summit e per informazioni agli investitori visitare mainzbiomed.com/investors/.
Mainz Biomed (NASDAQ:MYNZ) asistirá al 2025 Maxim Growth Summit en la ciudad de Nueva York los 22-23 de octubre de 2025 en The Hard Rock Hotel NYC. La compañía, que se centra en diagnósticos de genetica molecular para la detección temprana del cáncer, dijo que se reunirá cara a cara con inversores institucionales y analistas senior de Maxim durante el evento.
La cumbre cuenta con oradores principales y sesiones de mesa redonda en sectores que incluyen biotecnología, IA, terapia con células madre y más. Para la agenda del summit visite www.maximgrp.com/2025-growth-summit y para información a los inversores visite mainzbiomed.com/investors/.
Mainz Biomed (NASDAQ:MYNZ) 은 뉴욕시에서 열리는 2025 Maxim Growth Summit 에 참여할 것이며, 일정은 2025년 10월 22-23일로 The Hard Rock Hotel NYC에서 개최됩니다. 분자유전학 진단을 통한 조기 암 발견에 초점을 맞춘 이 회사는 행사 기간 동안 기관 투자자 및 Maxim의 수석 애널리스트들과 일대일로 만날 것이라고 밝혔습니다.
이번 정상회담은 기조연설과 원탁 토의 세션을 포함하며 생명공학, AI, 줄기세포 치료 등 다양한 분야를 다룹니다. 정상회담 일정은 www.maximgrp.com/2025-growth-summit에서 확인하고, 투자자 정보를 보려면 mainzbiomed.com/investors/를 방문하십시오.
Mainz Biomed (NASDAQ:MYNZ) assistera au 2025 Maxim Growth Summit à New York City les 22-23 octobre 2025 au The Hard Rock Hotel NYC. L'entreprise, spécialisée dans les diagnostics génétiques moléculaires pour la détection précoce du cancer, a déclaré qu'elle aura des entretiens individuels avec des investisseurs institutionnels et des analystes seniors de Maxim pendant l'événement.
Le sommet propose des conférences et des sessions de tables rondes dans des secteurs tels que la biotechnologie, l'IA, les thérapies par cellules souches et plus. Pour l'agenda du sommet, consultez www.maximgrp.com/2025-growth-summit et pour les informations destinées aux investisseurs, visitez mainzbiomed.com/investors/.
Mainz Biomed (NASDAQ:MYNZ) wird am 2025 Maxim Growth Summit in New York City am 22.-23. Oktober 2025 im The Hard Rock Hotel NYC teilnehmen. Das Unternehmen, das sich auf molekulargenetische Diagnostik für die Früherkennung von Krebs konzentriert, gab an, dass es während der Veranstaltung Einzelgespräche mit institutionellen Investoren und führenden Maxim-Analysten führen wird.
Der Gipfel bietet Hauptredner und Rundtisch-Sitzungen in Sektoren wie Biotechnologie, KI, Stammzelltherapien und mehr. Für die Agenda des Gipfels besuchen Sie www.maximgrp.com/2025-growth-summit und für Investoreninformationen besuchen Sie mainzbiomed.com/investors/.
Mainz Biomed (NASDAQ:MYNZ) ستحضر في قمة Maxim Growth 2025 في مدينة نيويورك يومي 22-23 أكتوبر 2025 في فندق The Hard Rock Hotel NYC. قالت الشركة، التي تركز على تشخيصات جينية جزيئية للكشف المبكر عن السرطان، إنها ستلتقي وجهاً لوجه مع مستثمرين مؤسسيين وكبار المحللين في Maxim خلال الحدث.
تضم القمة متحدثين رئيسيين وجلسات طاولة مستديرة عبر قطاعات بما في ذلك التكنولوجيا الحيوية، والذكاء الاصطناعي، وعلاج الخلايا الجذعية، والمزيد. لزيارة أجندة القمة، انقر على www.maximgrp.com/2025-growth-summit ولمعلومات المستثمرين تفضل بزيارة mainzbiomed.com/investors/.
Mainz Biomed (NASDAQ:MYNZ) 将出席在纽约市举行的 2025 Maxim Growth Summit，时间为 2025年10月22-23日，地点在 The Hard Rock Hotel NYC。该公司专注于分子遗传诊断以实现癌症的早期检测，并表示将在活动期间与机构投资者及 Maxim 的高级分析师进行一对一会谈。
峰会设有主旨演讲和圆桌讨论，涵盖生物技术、人工智能、干细胞治疗等多个领域。欲查看峰会日程，请访问 www.maximgrp.com/2025-growth-summit；欲了解投资者信息，请访问 mainzbiomed.com/investors/。
- None.
- None.
BERKELEY, Calif. and MAINZ, Germany, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today its participation in the upcoming 2025 Maxim Growth Summit, taking place October 22-23, 2025, at The Hard Rock Hotel NYC.
The prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries. Keynote speakers include Larry Kudlow (Broadcaster, Fox News) and Christopher Ruddy (CEO, Newsmax Media). The conference will also feature roundtable discussions with CEOs from small and mid-cap companies, moderated by Maxim Research Analysts. Roundtable discussions will cover a range of sectors, including biotechnology, stem cell therapy, ophthalmology, artificial intelligence, energy and mining, drones, and more.
Mainz Biomed will be meeting with institutional investors in a one-on-one format during the event, as well as senior Maxim analysts.
For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit.
Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook
About Mainz Biomed NV
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.
For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu
For investor inquiries, please contact ir@mainzbiomed.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company.
FAQ
When will Mainz Biomed (MYNZ) attend the Maxim Growth Summit in 2025?
Will Mainz Biomed (MYNZ) meet with investors at the 2025 Maxim Growth Summit?
Where can investors find the 2025 Maxim Growth Summit agenda mentioned by Mainz Biomed (MYNZ)?
What topics will be covered at the Maxim Growth Summit where Mainz Biomed (MYNZ) will attend?
Where can I find investor information for Mainz Biomed (MYNZ) referenced in the announcement?
